IMRI/SPECT GUIDED PROSTATE CANCER BIOPSY AND THERAPY

描述：(申请人描述) 而前列腺癌是#年最常见的诊断癌症。 美国男性和癌症死亡的第二大原因，技术和 工程技术的进步并没有推动诊断或治疗方法的进步 例如，当与脑癌相比时。这项研究的目的是 和开发项目是创建一种适合于空间的方法 前列腺癌的准确影像引导诊断和治疗。我们的方法 是基于介入性磁共振成像(IMRI)和 核成像，包括图像配准、图像引导活检和直接 监测热疗。为了测试我们的方法，我们将执行 在实验动物模型中进行仔细的验证测试以证明未来 临床试验和患者的临床评价。具体来说，我们将 获取骨盆的MRI体积扫描并将这些图像与核素配准 提供新陈代谢/单克隆性疾病指标的扫描。这是第一次 配准将半自动地将图像数据集与显著 不同的空间、对比度和信噪比特性。在指导期间， 前列腺病变，我们将比较新的快速MRI技术和改进的 对现有方法的运动免疫力，我们将完成开发和 两种IMRI导航方法的有效性验证，其中目标组织和 确保介入装置保持在扫描平面内。两种方法 经证明对IMRL指导的程序是可行的，将与 注册的数据集，以提供始终包括 介入性工具和靶组织以及对 同一方向的配准数据，以提高放置的精度 将工具放入最合适的组织位置。制导精度将达到 已验证。制导过程中的图像配准方法将提供准确的 在新的快速获取的数据和 以前登记的核和核磁共振数据作为一种方法来提高针对性 活组织检查和治疗。我们将开发新的方法来可视化信息， 例如介入工具的轨迹和组织温度并验证 他们的准确性。我们会尽可能使用幻影，但更重要的是，我们 将创建一个犬类模型来提供类似的组织变形， 人体预期的血流灌注、形态、器官和生理运动 审判。最后，我们将验证我们的图像引导活检和 现实条件下的影像引导微创治疗。

DESCRIPTION: (Applicant's Description) While adenocarcinoma of the prostate is the most commonly diagnosed cancer in American men and the second leading cause of cancer mortality, technologic and engineering advances have not pushed diagnosis or treatment methods forward when compared to, for example, brain cancers. The objective of this research and development project is to create a methodology suitable for spatially accurate image-guided diagnosis and treatment of prostate cancer. Our method is based around the newly emerging techniques in interventional MRI (IMRI) and nuclear imaging, including image registration, image guided biopsy, and direct monitoring of thermal therapy. To test our methodology, we will perform careful validation testing in an experimental animal model to justify future clinical trials and clinical evaluation in patients. Specifically, we will acquire MRI volume scans of the pelvis and register these images with nuclear scans that provide metabolic/monoclonal indicators of disease. This first registration will semi-automatically combine image data sets with markedly different spatial, contrast and SNR characteristics. During guidance to the prostate lesion, we will compare new rapid MRI techniques with improved immunity to motion to existing methods, and we will complete development and validation of two methods for IMRI navigation where the target tissue and the interventional device are ensured to remain in the scan plane. Two methods shown to be feasible for IMRl guided procedures will be integrated with registered data sets to provide both scan planes which always include the interventional tool and the target tissue and a best estimate of the registered data at the same orientation to improve accuracy of placement of the tools into the most appropriate tissue location. Guidance accuracy will be validated. Image registration methods during guidance will provide accurate automated multi-modality resolution between the new rapidly acquired data and previously registered nuclear and MRI data as a method to improve targeted biopsy and treatment. We will develop new methods to visualize information, like the interventional tool trajectory and tissue temperature and validate their accuracy. We will use phantoms when possible, but more importantly, we will create a canine model to provide comparable tissue deformation, perfusion, morphology and organ and physiologic motion expected in human trials. Finally, we will validate accuracy of both our image guided biopsy and image guided minimally invasive treatment under realistic conditions.